netFormulary The Pennine Acute Hospitals NHS
NHS Trust Formulary  
 Search
 Formulary Chapter 5: Infections - Full Chapter
Notes:
This chapter of the formulary is not an antibiotic prescribing guide and is not intended to guide treatment choice.

Please refer to the relevant Pennine Acute policies (e.g. the Antibiotic Policy for Adult Patients, or Antibiotic Guidelines for Paediatrics) when making treatment choices.
 Details...
05.03.03.02  Expand sub section  Chronic hepatitis C
Peginterferon Alfa
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
Injection 
Link  NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Link  NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Link  NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
   
Ribavirin (Copegus®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
Tablets 
Link  NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Link  NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Link  NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
   
Daclatasvir (Daklinza®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Tablets

Restricted Item  Requires MDT discussion with ID team 
Link  MHRA Safety Alert: Risk of hepatitis B reactivation with interferon-free regimens
Link  MHRA Safety Alert: Risk of interaction with vitamin K antagonists
Link  MHRA Safety Alert: Risk of severe bradycardia or heart block when taken with amiodarone
   
Dasabuvir (Exviera®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Tablets

Restricted Item Requires MDT discussion with ID team 
Link  MHRA Safety Alert: Risk of hepatitis B reactivation with interferon-free regimens
Link  MHRA Safety Alert: Risk of interaction with vitamin K antagonists
   
Elbasvir/Grazoprevir (Zepatier® 50mg/100mg)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Tablets

Restricted Item Requires MDT discussion with ID team 
Link  NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C
   
Ledipasvir/Sofosbuvir (Harvoni® 90mg/400mg)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Tablets

Restricted Item  Requires MDT discussion with ID team 
Link  MHRA Safety Alert: Risk of hepatitis B reactivation with interferon-free regimens
Link  MHRA Safety Alert: Risk of interaction with vitamin K antagonists
Link  MHRA Safety Alert: Risk of severe bradycardia or heart block when taken with amiodarone
   
Ombitasvir/Paritaprevir/Ritonavir (Viekirax® 12.5mg/75mg/50mg)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Tablets

Restricted Item  Requires MDT discussion with ID team 
Link  MHRA Safety Alert: interaction with levothyroxine
Link  MHRA Safety Alert: Risk of hepatitis B reactivation with interferon-free regimens
Link  MHRA Safety Alert: Risk of interaction with vitamin K antagonists
Link  MHRA Safety Alert: Ritonavir coadministration with a corticosteroid
   
Sofosbuvir (Sovaldi®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Tablets

Restricted Item  Requires MDT discussion with ID team 
Link  MHRA Safety Alert: Risk of hepatitis B reactivation with interferon-free regimens
Link  MHRA Safety Alert: Risk of interaction with vitamin K antagonists
Link  MHRA Safety Alert: Risk of severe bradycardia or heart block when taken with amiodarone
Link  NICE TA330: Sofosbuvir for treating chronic hepatitis C
   
Sofosbuvir / Velpatasvir (Epclusa®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
Tablets

Restricted Item  Requires MDT discussion with ID team 
Link  NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C
   
Sofosbuvir / Velpatasvir / Voxilaprevir (Vosevi®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
Tablets

Restricted Item  Requires MDT discussion with ID team 
Link  NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
   
Simeprevir (Olysio®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

Requires MDT discussion with ID team

For resistant cases only

 
Link  MHRA Safety Alert: Risk of severe bradycardia or heart block when taken with amiodarone
Link  NICE TA331: Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C
   
 ....
 Non Formulary Items
Boceprevir  (Victrelis®)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Red
High Cost Medicine
Link  NICE TA253: Boceprevir for the treatment of genotype 1 chronic hepatitis C
 
Ribavirin  (Rebetol®)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Red
 
Ribavirin  (Virazole®)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Red
 
Telaprevir  (Incivo®)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Red
High Cost Medicine
Link  NICE TA252:Telaprevir for the treatment of genotype 1 chronic hepatitis C
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Amber

Drugs designated amber are suitable for shared care arrangements under a shared care protocol. Prescribing may be transferred from secondary to primary care once the patient is stabilised and agreed shared care arrangements have been established. Alternatively primary care may initiate under the supervision of secondary care if this option is given in the shared care document. It is recommended that shared care arrangements should be drawn up following local discussion and agreement by prescribing parties.   

Black

These products have been reviewed by the GM Joint Formulary Group and have been deemed not suitable for prescribing for adults in primary or secondary care within Greater Manchester. These decisions have been made on the basis of safety, efficacy and cost-effectiveness of the products.  

Green

Not used   

Green 1

Drugs designated green1 are suitable for initiation and ongoing prescribing within primary care.   

Green 2

Drugs designated green2 can be initiated by primary care following written or verbal advice from a specialist and then be subsequently safely prescribed in primary care with little or no monitoring required.  

Green 3

Drugs designated green3 are suitable for on-going prescribing within primary care after specialist initiation and an initial review (unless specified) in secondary care. Little or no monitoring is required.  

Grey

Not suitable for routine prescribing but may be suitable for a defined patient population. Whilst prescribers should think very carefully before prescribing or recommending any of the products on the grey list, there may be exceptional instances when the use of one of these products is necessary for a particular patient.   

Red

Drugs designated red are considered to be specialist medicines and prescribing responsibility for these medicines should normally remain with the consultant or specialist clinician. These drugs should not be initiated or prescribed in primary care. It is recommended that the supply of these specialist medicines should be organised via the hospital pharmacy, this may include arranging for supply via a home care company.   

netFormulary